Bevacizumab Safety in Cancer Patients on Anticoagulation
Author Information
Author(s): Leighl N B, Bennouna J, Yi J, Moore N, Hambleton J, Hurwitz H
Primary Institution: Princess Margaret Hospital
Hypothesis
Does bevacizumab increase the risk of severe bleeding in cancer patients receiving therapeutic anticoagulation?
Conclusion
Bevacizumab did not increase the risk of severe bleeding in cancer patients who received therapeutic anticoagulation.
Supporting Evidence
- Severe bleeding event rates were similar in frequency between bevacizumab and placebo groups.
- No severe pulmonary bleeding was reported in any of the TA-treated populations.
- Venous thrombotic events were the most common reason for TA initiation.
Takeaway
This study looked at cancer patients taking a drug called bevacizumab along with blood thinners. It found that using both together doesn't make bleeding problems worse.
Methodology
The study analyzed data from three large, placebo-controlled clinical trials where patients received bevacizumab and therapeutic anticoagulation.
Limitations
The study did not collect specific information on the dosage, frequency, or duration of anticoagulant agents, and the number of bleeding events was relatively low.
Participant Demographics
Patients included those with metastatic colorectal cancer and advanced non-small cell lung cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website